Cargando…
Time to diagnosis of pulmonary hypertension and diagnostic burden: A retrospective analysis of nationwide US healthcare data
The main aim of this analysis was to investigate time from symptom onset (chronic unexplained dyspnoea [CUD]) to diagnosis of Group 1 pulmonary hypertension (PH)—pulmonary arterial hypertension (PAH)—and to characterize healthcare resource utilization leading up to diagnosis using a nationwide US cl...
Autores principales: | Didden, Eva‐Maria, Lee, Eileen, Wyckmans, Julie, Quinn, Deborah, Perchenet, Loïc |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9843478/ https://www.ncbi.nlm.nih.gov/pubmed/36694845 http://dx.doi.org/10.1002/pul2.12188 |
Ejemplares similares
-
Evaluation of code-based algorithms to identify pulmonary arterial
hypertension and chronic thromboembolic pulmonary hypertension patients in large
administrative databases
por: Sprecher, Viviane P., et al.
Publicado: (2020) -
Initial combination therapy of macitentan and tadalafil in pulmonary arterial hypertension
por: Sitbon, Olivier, et al.
Publicado: (2020) -
Healthcare burden of pulmonary hypertension owing to lung disease and/or hypoxia
por: Heresi, Gustavo A., et al.
Publicado: (2017) -
The economic burden of pulmonary arterial hypertension (PAH) in the US on payers and patients
por: Sikirica, Mirko, et al.
Publicado: (2014) -
Incident and prevalent cohorts with pulmonary arterial hypertension: insight from SERAPHIN
por: Simonneau, Gérald, et al.
Publicado: (2015)